A new study examined organizational differences of whole-brain networks between MS and NMOSD in a prospective cohort of patients with CNS demyelinating disease. All 144 study participants, including ...

Please provide your email address to receive an email when new articles are posted on . In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its ...

Transverse myelitis in a patient with neuromyelitis optica spectrum disorder Three agents were recently FDA approved for NMOSD in adults who are AQP4 antibody positive: eculizumab, inebilizumab-cdon, ...

Neuromyelitis optica spectrum disorder (NMOSD) is neuroinflammatory disease characterized by optic neuritis and myelitis with presence of anti-aquaporin-4 (AQP4) antibodies. Satralizumab is an anti-IL ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

In patients with NMOSD, there is a decline in executive function in terms of sustained attention, phonological verbal fluency, and working memory. Neuropsychological assessments in the clinical ...

In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143). Treatment with Soliris (eculizumab; Alexion) was associated ...

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that mostly affects your eyes and spinal cord. Your immune system attacks a specific protein, called aquaporin-4 (AQP4). The ...

The FDA has approved Soliris (eculizumab; Alexion Pharmaceuticals, Inc) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody ...

The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...

– First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks – – First ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...